phase II clinical study
FDA Reviewing Iovance's BLA for Melanoma TIL Therapy; Decision Expected in November
Iovance said the FDA is reviewing its BLA, and if successful, lifileucel could be the first autologous cell therapy approved for solid cancer.
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout
Around 18 percent of patients in a Phase I/II trial with aggressive, treatment-refractory forms of leukemia had complete responses on the CAR T-cell therapy.
Ideaya Biosciences, Amgen Starting Phase I/II Trial of Targeted Treatment Combo in MTAP-Null Tumors
The US Food and Drug Administration cleared the firms' investigational new drug application to evaluate IDE397 plus AMG193 in an Amgen-sponsored trial.
Panbela Therapeutics, Moffitt Cancer Center Testing Immunotherapy Enhancer in STK11-Mutant NSCLC
The partners will evaluate Panbela's eflornithine with Merck's Keytruda in a Phase I/II trial as proof of concept for modulating the immune system using polyamines and standard therapies.
Myeloid Therapeutics Closes $73M Financing to Advance Immunotherapy Pipeline
The funds will support clinical development of Myeloid's pipeline of targeted next generation cell- and mRNA-based therapies in cancer indications.